UPDATE: Dr. Sanjay Kaul was bounced from the FDA's prasugrel panel after Eli Lilly called the FDA to question his inclusion on the panel, according to HeartWire. The FDA has admitted it made a ...
About Prasugrel Daiichi Sankyo Company, Limited, and Eli Lilly and Company co-developed prasugrel, an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube ...
For those of you wondering why Eli Lilly would volunteer to have its stock crushed by the loss of cash and added debt required to buy ImClone, here's one idea: The deal makes more sense if Lilly ...
Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary ...
Please provide your email address to receive an email when new articles are posted on . Results of the RAPID Primary PCI study indicate that prasugrel is noninferior compared with ticagrelor in terms ...
Jacksonville, FL - Data from a pharmacodynamic study suggests that acute coronary syndrome (ACS) patients can be safely switched from maintenance clopidogrel (Plavix, Bristol-Myers ...
The authors of this study evaluated the relationship between genetic variants, drug metabolism, and clinical effectiveness of prasugrel. First, they sought to identify genetic variants that might ...
The newer antiplatelet agent prasugrel was no better than the old standby clopidogrel for treating patients with acute coronary syndrome (ACS) who are not undergoing revascularization. The results of ...
NEW ORLEANS (Reuters) - Researchers have overestimated the ability to administer Eli Lilly and Co's experimental prasugrel blood thinner without causing dangerous bleeding, a prominent cardiologist ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Efficacy is established in randomized clinical trials. Effectiveness, however, is established in ...
Uncertainty over when, or if, the U.S. Food and Drug Administration will approve prasugrel, a blood-thinner Eli Lilly and Co. hopes will be its next blockbuster, has taken a bite out of the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results